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Background: Depression is common and has a significant impact on quality of life
for many people with multiple sclerosis (MS). A preventive management approach via
modification of lifestyle risk factors holds potential benefits. We examined the relationship
between modifiable lifestyle factors and depression risk and the change in depression
over 2.5 years.
Methods: Sample recruited using online platforms. 2,224 (88.9%) at baseline and 1,309
(93.4%) at 2.5 years follow up completed the necessary survey data. Depression risk
was measured by the Patient Health Questionnaire-2 (PHQ-2) at baseline and Patient
Health Questionniare-9 (PHQ-9) at 2.5-years follow-up. Multivariable regression models
assessed the relationships between lifestyle factors and depression risk, adjusted for sex,
age, fatigue, disability, antidepressant medication use, and baseline depression score, as
appropriate.
Results: The prevalence of depression risk at 2.5-years follow-up in this cohort was
14.5% using the PHQ-2 and 21.7% using the PHQ-9. Moderate alcohol intake, being a
non-smoker, diet quality, no meat or dairy intake, vitamin D supplementation, omega 3
supplement use, regular exercise, and meditation at baseline were associated with lower
frequencies of positive depression-screen 2.5 years later. Moderate alcohol intake was
associated with greater likelihood of becoming depression-free and a lower likelihood
of becoming depressed at 2.5-years follow-up. Meditating at least once a week was
associated with a decreased frequency of losing depression risk, against our expectation.
After adjusting for potential confounders, smoking, diet, physical activity, and vitamin D
and omega-3 supplementation were not associated with a change in risk for depression.
Taylor et al. Lifestyle and Depression in MS
Conclusion: In a large prospective cohort study of people with MS and depression,
in line with the emerging treatment paradigm of early intervention, these results suggest
a role for some lifestyle factors in depression risk. Further studies should endeavor to
explore the impact of positive lifestyle change and improving depression in people living
with MS.
Keywords: Multiple sclerosis, epidemiology, depression, lifestyle, longitudinal, cohort study (or longitudinal study)
INTRODUCTION
Multiple sclerosis (MS) is an autoimmune, demyelinating,
inflammatory disease of the central nervous system. Symptoms
are diverse and can include sensory, motor and visual deficits,
bowel and bladder dysfunction, cognitive impairment and
fatigue. Neuropsychiatric symptoms are also common, with an
episode of depression occurring for 50% of people with MS
during their lifetime (1); the annual prevalence of depression has
been estimated as 20% (2), increasing to 25% among people in
the 18–45 years old age range (3).
In addition to its negative impacts on overall quality of
life, depression is associated with suicide, a significant cause of
mortality for people with MS (4). People with MS have both
a higher suicide rate (5) and all-cause mortality rate compared
to the general population (4), with up to 35% of people with
MS reporting suicidal ideation during their lifetime (6). Suicidal
ideation is strongly associated with depression and can be present
even if depressive symptoms are mild (6). However, a greater
severity of depression shows an even stronger association with
suicidal thoughts (7). Suicidal ideation is associated with both
actual and perceived disability, with depression a mediating
factor in this relationship. Depression is therefore a modifiable
factor, potentially via both prevention and treatment, to reduce
the risk of suicide and improve mortality outcomes for people
with MS (6).
The evidence base for treatment of depression for people
with MS is limited. Pharmacological and psychological treatment
are the mainstay in management: prescription of antidepressant
medication for people with MS is widespread and there is a
clear need to establish the evidence base behind this practice
(8). The most recent Cochrane review of pharmacological
treatment reported a trend toward efficacy for two antidepressant
medications, but cautioned about the significant methodological
problems of the research, high rates of adverse effects, and issues
regarding loss to follow-up which may affect generalizability
(9). A more recent review of clinical trials recommended
antidepressant medication choice be based on the medication
side effect profile and tailored for the individual, as the side
effects of antidepressant medications can worsen common
symptoms of MS, such as fatigue, sexual dysfunction, and
bowel/bladder dysfunction (10). Most non-pharmacological
research investigating the management of depression in MS has
focused on psychological interventions, particularly cognitive
behavioral therapy (11). A recent meta-analysis of cognitive
behavioral therapy showed a moderate effect on depression in
the short term for people with MS (11). Exercise therapy for
depression is increasingly common and effective in the general
population (12), and has also shown promise for people with MS
(13). Mindfulness-based interventions for people with MS have
also been shown to improve depression and quality of life at 6
months follow-up (14).
The challenge of treating depression extends to the
general population where pharmacological and psychological
interventions are also first-line treatments, yet have limited
impact, only reducing the burden of depression by 10–30%
(15). An emerging paradigm which provides a nexus between
prevention, health promotion and clinical treatment of
depression, is modification of known lifestyle risk factors for
depression (16, 17). In the general population, prospective
studies in teenagers and adults showed that modification of
lifestyle factors, including diet, exercise, weight and smoking,
improved and prevented depression (18, 19).
As part of the wider Health Outcomes and Lifestyle In a
Sample of people with Multiple Sclerosis (HOLISM) Study,
we previously described the results from our baseline cross-
sectional study of 2,466 participants with MS (20), finding
19.3% screened positive for depression using the Patient
Health Questionnaire-2 (21). We demonstrated strong and
clinically meaningful associations between modifiable lifestyle
risk factors and depression prevalence. In our current study, we
investigated whether modifiable lifestyle factors were associated
with screening positive for depression 2.5 years after our baseline
study and the predictors of change in depression screen during
follow-up.
METHODS
Participants and Recruitment
The methodology for the HOLISM study has previously been
documented in detail at both baseline and 2.5-years follow-up
(22, 23). Briefly, participants were recruited via online platforms
that engaged people with MS. Participants used SurveyMonkey R©
to complete the survey and to provide informed consent.
Participants were eligible if they reported having been diagnosed
with MS by a medical doctor and were over 18 years old. Ethics
approval was granted by St Vincent’s Hospital Melbourne HREC
initially, and the Health Sciences Human Ethics Subcommittee at
the University of Melbourne (Ethics ID: 1545102).
Data Collection and Tools Used
Many of the same measures used at baseline were
employed at follow-up to allow longitudinal analysis. A
range of sociodemographic, behavioral/environmental, and
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clinical parameters were queried by participant-completed
questionnaires (22). Particular elements queried are described
below.
Sociodemographic and Biometric Data
Data were collected on sex, age, height, weight, country of birth
and residence, marital status, education level, employment and
socioeconomic status among others.
Dietary Habits
We used a modified version of the Diet Habits Questionnaire
(DHQ) (24) as previously described (22, 23). A higher score
indicated a healthier diet and data were grouped into quartiles
of their total score.
Vitamin D Supplementation
Participants were asked if they took a vitamin D supplement, the
amount taken, frequency and duration of supplementation (22).
Omega-3 Supplementation
We assessed both the type and dose of omega-3 supplementation
used by participants (22).
Exercise
We used the International Physical Activity Questionnaire-Short
Form (IPAQ-SF) (25), which assesses the frequency and duration
of moderate and vigorous physical activity over the preceding
7 days. Data were categorized as low, moderate or high activity
level according to the IPAQ guidelines.
Meditation
We assessed how often participants meditated on average per
week and for how long each time (22).
Alcohol
We asked participants the frequency and volume of alcohol
consumed, providing participants information of what a
standard drink was. Data was then re-calculated in grams of
alcohol to derive variables of low, moderate and high alcohol
intake (26).
Smoking
Participants smoking behavior was queried and these then
classified as being a never smoker, ex-smoker or current smoker.
Depression
At 2.5-years follow-up, we used the Patient Health
Questionnaire-9 (PHQ-9) to assess depression risk (27).
The PHQ-9 is a nine-question instrument that is widely used
and has been validated in MS research (28). The PHQ-2 was
used at baseline and includes two items of the PHQ-9, allowing
calculation of PHQ-2 and PHQ-9 scores at follow-up review,
and thus change in PHQ-2 between reviews. We used the PHQ-9
at follow-up due to its superior psychometric assessment to
substantiate findings from baseline.
Participants were asked the frequency of the specific symptom
in the past 2 weeks, with answers including “Not at all,” “Several
days,” “More than half the days,” and “Nearly every day.” At least
one of the asterixed two symptoms must be present for diagnosis
of a Major Depressive Episode (29) and these items are included
in the PHQ-2.
1) Little interest or pleasure in doing things∗
2) Feeling down, depressed or hopeless∗
3) Trouble falling asleep or staying asleep, or sleeping too much
4) Feeling tired or having little energy
5) Poor appetite or overeating
6) Feeling bad about yourself–or that you are a failure or having
let yourself or your family down
7) Trouble concentrating on things, such as reading the
newspaper or watching television
8) Moving or speaking so slowly that other people could have
noticed; or the opposite, being so fidgety or restless that you
have been moving around a lot more than usual
9) Thoughts that you would be better off dead or hurting
yourself in some way.
The PHQ-2 score ranges from 0 to 6 with scores >2
indicating a positive depression screen. The PHQ-9 score ranges
0–27, with scores >9 indicating positive depression-screen.
Additionally, the PHQ-9 can be subdivided into grades of
severity: 5–9 indicating minimal depression, 10–14 indicating
mild depression, 15–19 indicating moderate depression, and 20–
27 indicating severe depression. Moderate and severe depression
were combined due to cell-size constraints (n = 37 with severe
depression).
Clinical Measures
Disability was assessed using the Patient-Determined Disease
Steps (PDDS) scale (30), from which the disease-duration
adjusted Patient-derived Multiple Sclerosis Severity Score
(P-MSSS) was calculated (31). Fatigue was assessed using the
Fatigue Severity Scale (FSS) (32). Immunomodulatorymedication
use, including interferon-beta-based medication, glatiramer
acetate, alemtuzumab, cladribine, daclizumab, dimethyl
fumarate, fingolimod, laquinimod, rituximab, teriflunomide, and
natalizumab, as well as prescription antidepressant and anxiolytic
medication use were queried at each review.
Data Analysis
Log-binomial regression models were used to evaluate
associations of sociodemographic and lifestyle factors with
positive depression-screen at follow-up, estimating a prevalence
ratio. Log-multinomial regression models (33) were used to
evaluate predictors of severity of PHQ-9 positive depression-
screen.Multivariable models at 2.5-years follow-up were adjusted
for contemporaneous P-MSSS, age, fatigue, and antidepressant
medication use, these covariates were selected based on review of
the literature for relevant characteristics and on material impact
on models.
Log-binomial regression were used to evaluate
sociodemographic and lifestyle factors associated with change
in PHQ-2-defined depression-screen between baseline and
2.5-years follow-up. We estimated a risk ratio for baseline
predictors and a prevalence ratio where change in determinants
was evaluated against change in depression-screen state. In
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these data analyses, those who changed from positive to negative
depression-screen were compared to those who screened positive
for depression at both timepoints, while those who changed
from negative to positive depression-screen were compared to
those who screened negative for depression at both timepoints.
Multivariable models for predictors of change in depression-
screen were adjusted for P-MSSS, age, fatigue, antidepressant
medication use, and baseline continuous PHQ-2 score, these
covariates were selected based on review of the literature for
relevant characteristics and on material impact on models.
All multivariable models were done using complete-case
analysis, that is they were constrained to those who had data on
all the model covariates.
STATA/SE 15.0 (StataCorp, College Park, TX, USA) was used
to analyse the data as previously described.
RESULTS
At baseline review, 2,466 participants with MS initiated the
questionnaire, of whom 2,224 (88.9%) completed the PHQ-2
instrument. At 2.5-years follow-up review, 1,401 participants
with MS initiated the questionnaire, of whom 1,309 (93.4%)
completed the PHQ-2 instrument and 1,264 (90.2%) completed
the PHQ-9 instrument. The prevalence of depression at 2.5-
years review differed between the PHQ-2 and PHQ-9, the PHQ-2
estimating a prevalence of 14.5%, while the PHQ-9 estimated a
prevalence of 21.7%.
As described elsewhere (22, 23, 26) the cohort was largely
female at both timepoints, of mean age in the mid-40s, and,
while the mean BMI was in the overweight range, the cohort
consistently engaged in healthy behaviors, including >90% non-
smoking, over half engaging in regular physical activity, and large
proportions reporting vitamin D and omega-3 supplement use.
Alcohol consumption was common, only around 20% reporting
not drinking alcohol at either timepoint, though of those using
alcohol, the majority drank low/moderate amounts. Diet quality
scores were good, with average scores of 81 at both timepoints,
particularly driven by high sub-scores in not having snacks and
takeaway, lower fat consumption, and healthier food choices
(data not shown). Other cohort characteristics are shown in
Table 1.
Determinants of Depression at 2.5-Years
Follow-Up
Current smokers were significantly more likely to have scores
indicative of prevalent depression risk, both PHQ-2 and PHQ-
9 (Table 2). Alcohol, on the other hand, showed a significant
inverse association with depression risk, showing evidence of
a dose-dependent association, particularly PHQ-9. Examining
alcohol load found this association was solely driven by
low/moderate consumption, with high alcohol consumption not
significantly associated with depression risk (data not shown).
Higher diet quality scores also showed a dose-dependent
association with lower frequencies of depression, though
adjustment attenuated these associations. Those reporting
consuming meat and dairy had higher frequencies of depression
TABLE 1 | Cohort characteristics at baseline and 2.5-yr follow-up, and
characteristics of those retained at 2.5-years review vs. those lost to follow-up.
Baseline
(n = 2,466)
Baseline, completed
2.5-years
(n = 1,401)
2.5-years
(n = 1,401)
PHQ-2 SCORE > 2
No depression risk 1,799 (80.9%) 1,139 (86.3%) 1,119 (85.5%)
Depression risk 425 (19.1%) 181 (13.7%) 190 (14.5%)‡
(Missing) (242 (9.8%)) (81 (5.8%)) (92 (6.6%))‡
PHQ-9 SCORE
0–4: normal 607 (48.0%)
5–9: minimal
depression symptoms
383 (30.3%)
10–14: major
depression, mild
144 (11.4%)
15–19: major
depression, moderate
93 (7.4%)
≥20: major depression,
severe
37 (2.9%)
(Missing) (137 (9.8%))
PHQ-9 SCORE > 9
No depression risk 990 (78.3%)
Depression risk 274 (21.7%)
(Missing) (137 (9.8%))
REGION OF RESIDENCE
Australasia 835 (34.0%) 560 (40.1%) 564 (40.3%)
Europe 648 (26.4%) 380 (27.2%) 378 (27.0%)
North America 913 (37.1%) 426 (30.5%) 430 (30.7%)‡
Other 63 (2.6%) 30 (2.2%) 29 (2.1%)
(Missing) (7 (0.3%)) (5 (0.4%)) (0 (0%))
SEX
Male 415 (17.6%) 241 (17.3%) 241 (17.3%)
Female 1,937 (82.4%) 1,150 (82.7%) 1,150 (82.7%)
(Missing) (114 (4.6%)) (10 (0.7%)) (10 (0.7%))‡
SMOKE TOBACCO?
Never 1,099 (48.0%) 707 (52.7%) 701 (52.7%)
Ex-smoker 908 (39.7%) 520 (38.8%) 527 (39.6%)
Current smoker 281 (12.3%) 114 (8.5%) 102 (7.7%)‡
(Missing) (178 (7.2%)) (60 (4.3%)) (71 (5.1%))
ALCOHOL INTAKE
Non-drinker 415 (18.2%) 215 (16.1%) 263 (20.7%)
<Once per week 897 (39.3%) 500 (37.3%) 411
(32.4%)
†
b
1–3 days per week 567 (24.8%) 362 (27.0%) 347 (27.3%)a
4–7 days per week 406 (17.8%) 265 (19.8%) 249 (19.6%)a
(Missing) (181 (7.3%)) (59 (4.2%)) (131 (9.4%))a
ALCOHOL LOAD, STANDARD DRINKS PER DAYc
Low 882 (41.3%) 461 (36.2%) 102 (9.5%)
Moderate 970 (45.4%) 631 (49.6%) 812
(75.8%)‡b
High 286 (13.4%) 180 (14.2%) 157
(14.7%)‡b
(Missing) (328 (13.3%)) (129 (9.2%)) (330
(23.6%))‡b
PHYSICAL ACTIVITY
Low activity 752 (36.2%) 423 (34.0%) 396 (31.8%)
Moderate activity 839 (40.4%) 533 (42.8%) 582 (46.7%)
†
(Continued)
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TABLE 1 | Continued
Baseline
(n = 2,466)
Baseline, completed
2.5-years
(n = 1,401)
2.5-years
(n = 1,401)
High activity 485 (23.4%) 290 (23.3%) 269 (21.6%)
(Missing) (390 (15.8%)) (155 (11.1%)) (154
(11.0%))
†
DIET–CONSUMES MEAT?
No 761 (33.2%) 532 (39.6%) 513 (38.5%)
Yes 1,533 (66.8%) 813 (60.5%) 820 (61.5%)
†
(Missing) (172 (7.0%)) (56 (4.0%)) (68 (4.9%))
†
DIET–CONSUMES DAIRY?
No 862 (37.9%) 580 (43.4%) 564 (42.4%)
Yes 1,415 (62.1%) 756 (56.6%) 765 (57.6%)
†
(Missing) (189 (7.7%)) (65 (4.6%)) (72 (5.1%))‡
TAKING A VITAMIN D SUPPLEMENT?
No 601 (24.4%) 271 (19.3%) 271 (19.3%)
Yes 1,865 (75.6%) 1,130 (80.7%) 1,130
(80.7%)‡
TAKING AN OMEGA-3 SUPPLEMENT?
No 998 (40.5%) 469 (33.5%) 542 (38.7%)
Yes 1,468 (59.5%) 932 (66.5%) 859 (61.3%)a
TYPE OF MS AT COMPLETION OF SURVEY
Benign 100 (4.1%) 64 (4.6%) 85 (6.2%)
†
a
RRMS 1,491 (61.6%) 875 (63.3%) 810 (59.2%)
SPMS 275 (11.4%) 144 (10.4%) 199
(14.6%)
†
a
PPMS 175 (7.2%) 100 (7.2%) 111 (8.1%)
PRMS 48 (2.0%) 18 (1.3%) 23 (1.7%)
Unsure/other 330 (13.6%) 181 (13.1%) 140 (10.2%)
†
(Missing) (47 (1.9%)) (19 (1.4%)) (33 (2.4%))a
TAKING ANY OF THE 11 SPECIFIED
IMMUNOMODULATORY MEDICATIONS?
No 1,321 (53.6%) 747 (53.3%) 812 (58.0%)
Yes 1,145 (46.4%) 654 (46.7%) 589
(42.0%)
†
a
TAKING PRESCRIPTION ANTIDEPRESSANT MEDICATION?
No 1,964 (79.6%) 1,158 (82.7%) 1,149 (82.0%)
Yes 502 (20.4%) 243 (17.3%) 252 (18.0%)
TAKING PRESCRIPTION ANXIOLYTIC MEDICATION?
No 2,211 (89.7%) 1,282 (91.5%) 1,285 (91.7%)
Yes 255 (10.3%) 119 (8.5%) 116 (8.3%)
†
MEDITATES AT LEAST WEEKLY?
No 1,566 (69.8%) 893 (67.2%) 850 (65.0%)
Yes 677 (30.2%) 436 (32.8%) 457 (35.0%)
†
(Missing) (223 (9.0%)) (72 (5.1%)) (94 (6.7%))
Mean
(SD; range)
Age 45.7
(10.5;
17.5–79.0)
45.9
(10.5; 17.9–79.0)
48.4‡b
(10.5;
19.3–81.5)
BMI 25.8
(6.5;
14.6–71.0)
25.2
(5.9; 15.4–57.7)
25.4
(6.0;
14.4–64.1)
(Continued)
TABLE 1 | Continued
Baseline
(n = 2,466)
Baseline, completed
2.5-years
(n = 1,401)
2.5-years
(n = 1,401)
Median
(interquartile range)
PHQ-2 0
(0–1)
1
(0–2)
0‡
(0–1)
PHQ-9 0
(0–0)
IPAQ MET mins per
week
1,092
(297–2,826)
1,200
(396–2,826)
1,200
(396–2,670)
DHQ total score 81
(71–89.5)
83
(73.5–91)
81a
(71–90)
Disease duration since
symptom onset, years
11.8
(6.2–20.4)
11.4
(5.4–20.2)
14.2‡b
(8.1–23.2)
PDDS 2
(0–4)
1
(0–4)
1
(0–4)
P-MSSS 4.7
(2.6–7.4)
4.4
(2.4–7.3)
4.9a
(2.6–7.3)
Fatigue Severity Score 44
(29–55)
42
(27–54)
42
†
(26–54)
Differences between categorical variables assessed by multinomial logistic regression.
Differences between normally distributed continuous terms assessed by two-tailed t-test.
Differences between non-normally distributed continuous terms assessed by Kruskal-
Wallis rank test.
†
p < 0.05 for differences between baseline and 2.5-years review.
‡p < 0.001 for differences between baseline and 2.5-years review.
ap < 0.05 for differences between baseline and 2.5-years review for participants with
2.5-years follow-up data.
bp < 0.001 for differences between baseline and 2.5-years review for participants with
2.5-years follow-up data.
cAlcohol intake was categorized specific to sex, such that low alcohol intake was defined
as <15 grams of alcohol per week, moderate was up to 30 grams alcohol per day for
females and up to 45 grams alcohol per day for males, and heavy was over 30 grams
alcohol per day for females and over 45 grams alcohol per day for males.
Note: some variables have missing values but where there were no missing values, this
row is not shown for that variable.
BMI, body mass index; DHQ, Dietary Habits Questionnaire; IPAQ, International
Physical Activity Questionnaire; PDDS, Patient-Determined Disease Steps Scale; PHQ,
Patient Health Questionnaire; P-MSSS, Patient Determined Multiple Sclerosis Severity
Score; PPMS, primary progressive multiple sclerosis; PRMS, progressive-relapsing
multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SCQ, Self-administered
Comorbidity Questionnaire; SPMS, secondary progressive multiple sclerosis.
at follow-up, especially the PHQ-9, though adjustment
attenuated all these associations. Both vitamin D and omega-3
supplementation were associated with lower frequencies of
depression risk by both PHQ-2 and PHQ-9. However, while
the associations of vitamin D supplementation persisted on
adjustment, omega-3 associations were greatly attenuated.
Greater physical activity was associated with a significantly
lower depression risk, robust to adjustment. Likewise, meditation
was associated with significantly reduced prevalence of
depression by both scores, though only that for PHQ-9
persisted on adjustment.
Determinants of PHQ-9 Grade of
Depression at 2.5-Years Follow-Up
Many of the factors associated with overall depression risk (PHQ-
9 > 9) in Table 2 were also associated with the gradations of
depression severity (Table 3). The positive associations of current
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smoking with depression risk were much stronger for major
depression. There was an inverse association between alcohol and
overall depression risk, only evident for major depression, while
no associations were seen for minimal depression symptoms.
As with overall depression risk, however, while both moderate
and high alcohol intake were inversely associated with major
depression risk, there was no benefit of high alcohol intake with
depression (data not shown).
Higher diet quality was associated with a significantly
reduced risk of depression, most strongly with major depression.
Likewise, for meat and dairy consumption, the positive
associations were much stronger with severe depression. Vitamin
D and omega-3 supplementation both showed strong and
significant inverse associations with major depression risk.
The association of physical activity with depression was only
evident for major depression, showing no associations with
minimal depression symptoms. For major depression, however,
those engaging in more physical activity had markedly lower
frequencies of major depression, over 50%. Meditation, on
the other hand, while strongly associated with PHQ-9 overall,
showed no material dose-dependency, only being significantly
associated with mild major depression.
Baseline and Trajectory Determinants of
Change in PHQ-2 Depression Between
Baseline and 2.5-Years Follow-Up
A change in PHQ-2 depression was evaluated as a change
in state between baseline and 2.5-years follow-up, such that
participants could go from having not screened positive for
depression at baseline to positive screen at follow-up (“becoming
depressed”), screening positive for depression at baseline and
losing this at follow-up (“losing depression”), or having no
change, this including screening positive for depression or not at
both timepoints (Table 4). For trajectory analysis, then, gaining
depression risk was compared against those without depression
risk at both time points, while losing depression risk was
compared against those with depression risk at both time points.
While there was some indication that smoking had a
prospective association with subsequently becoming depressed,
these associations were essentially abrogated on adjustment.
Alcohol consumption, on the other hand, was associated with
greater risk of losing depression and lower risk of becoming
depressed, much more robust to adjustment. As seen with cross-
sectional depression, there was no association of high alcohol
consumption with change in depression state, suggesting these
associations are particular to moderate alcohol intake. Higher
diet quality showed a prospective association with reduced
risk of becoming depressed, fairly robust to adjustment. Meat
and dairy consumption were inconsistently associated with
change in depression, with some indication that consumption
was associated with becoming depressed, but these associations
largely attenuated on adjustment. Vitamin D supplementation
showed a strong association with a reduced risk of becoming
depressed, robust to adjustment. Omega-3 supplementation
was not associated with either becoming depressed or losing
depression.
Overall physical activity was not associated with change in
depression state. Of interest, those who reported meditating
at least weekly at baseline had a significantly reduced risk of
losing depression, robust to adjustment, though there was no
association of meditation with risk of gaining depression.
DISCUSSION
Depression is common (1), poorly treated, under-diagnosed
(34) and has been reported to exert the greatest influence on
quality of life for people with MS, irrespective of disability level
(35). In the general population, depression typically has a strong
genetic basis and has episodes with full or partial recovery (29).
However, for people with MS, depression is persistent (8) and
genetic determinants are not the primary drivers (1). Instead,
for people with MS depression is likely due to the psychological
adjustment to the illness, as well as underlying physiological
processes driving the disease. While it is well-established
that the underlying processes of MS are multifactorial,
including neurodegeneration, autoimmunity and inflammation;
depression has more recently been recognized as having an
inflammatory component mediated by modifiable lifestyle
factors (16, 36). Lifestyle factors, combined with the stress of
diagnosis and adjustment to illness, may cause overactivation
of the hypothalamus-pituitary-adrenal axis, increasing cortisol
and systemic inflammation (16). Identification of risk factors
for MS and depression and their link via the common pathway
of inflammation opens the critical avenue for preventive
and therapeutic interventions (20, 36) potentially leading to
improved morbidity and mortality outcomes.
In the current study, we have completed a comprehensive
investigation of modifiable lifestyle factors associated with
screening positive for depression, and the predictors of change
in depression state over 2.5 years of follow-up. Moderate alcohol
use was associated with lower depression risk, particularly severe
depression at 2.5-years follow-up, which is consistent with our
baseline findings (20). These results are also in keeping with the
literature, where moderate alcohol intake has been associated
with better mental health-related quality of life in MS (26).
In the general population, moderate alcohol intake has been
associated with lower rates of depression in primary care settings
(37). Beyond the association of alcohol use and depression, we
found that moderate alcohol intake was associated with greater
risk of losing depression and lower risk of becoming depressed.
These data are supported by findings in the general population
that moderate alcohol intake is associated with lower incidence
of becoming depressed (38). Moderate alcohol intake results
in significant reduction of proinflammatory cytokines (39),
reducing inflammation, suggesting a mechanism of preventing
and potentially treating depression. Heavy alcohol use or alcohol
dependence, on the other hand, is harmful for general health
and increases the prevalence of depression in both the general
population and MS (37, 38, 40). Our HOLISM findings are
consistent with this literature, finding no beneficial association of
heavy alcohol intake and depression trajectory, nor with mental
or physical health benefits (20, 26).
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TABLE 2 | Predictors of depression risk at 2.5-years follow-up.
PHQ-2 PHQ-9
n/N with PHQ-2 > 2 (%) Univariable Adjusted N with PHQ-9 > 9 (%) Univariable Adjusted
SMOKE TOBACCO?
Never 84/695 (12.1%) 1.00 [Reference] 1.00 [Reference] 121/677 (17.9%) 1.00 [Reference] 1.00 [Reference]
Ex-smoker 78/513 (15.2%) 1.26 (0.95, 1.68) 1.20 (0.91, 1.58) 107/491 (21.8%) 1.22 (0.97, 1.54) 1.13 (0.90, 1.41)
Current smoker 28/99 (28.35) 2.34 (1.61, 3.40) 1.63 (1.12, 2.37) 46/94 (48.9%) 2.74 (2.11, 3.56) 1.96 (1.51, 2.55)
Trend: p < 0.001 p = 0.016 p < 0.001 p < 0.001
ALCOHOL INTAKE
Non-drinker 45/256 (17.6%) 1.00 [Reference] 1.00 [Reference] 69/246 (28.1%) 1.00 [Reference] 1.00 [Reference]
<Once per week 69/405 (17.0%) 0.97 (0.69, 1.36) 1.04 (0.74, 1.45) 98/387 (25.3%) 0.90 (0.69, 1.18) 0.89 (0.69, 1.15)
1–3 days per week 41/342 (12.0%) 0.68 (0.46, 1.01) 0.82 (0.55, 1.20) 59/333 (17.7%) 0.63 (0.47, 0.86) 0.74 (0.55, 0.99)
4–7 days per week 27/245 (11.0%) 0.63 (0.40, 0.98) 0.83 (0.54, 1.27) 39/240 (16.3%) 0.58 (0.41, 0.82) 0.74 (0.53, 1.03)
(Missing) p = 0.007 p = 0.18 p < 0.001 p = 0.030
ALCOHOL LOADa
Low 21/102 (20.6%) 1.00 [Reference] 1.00 [Reference] 29/97 (29.9%) 1.00 [Reference] 1.00 [Reference]
Moderate 109/799 (13.6%) 0.66 (0.44, 1.01) 0.80 (0.53, 1.23) 151/775 (19.5%) 0.65 (0.47, 0.91) 0.77 (0.56, 1.06)
High 21/156 (13.5%) 0.65 (0.38, 1.14) 0.84 (0.48, 1.45) 34/154 (22.1%) 0.74 (0.48, 1.13) 0.97 (0.65, 1.45)
Trend: p = 0.19 p = 0.52 p = 0.32 p = 0.98
DHQ TOTAL SCORE
32–70 74/336 (22.0%) 1.00 [Reference] 1.00 [Reference] 111/323 (34.4%) 1.00 [Reference] 1.00 [Reference]
>70–80 51/320 (15.9%) 0.72 (0.52, 1.00) 0.80 (0.58, 1.11) 83/309 (26.9%) 0.78 (0.62, 0.99) 0.87 (0.69, 1.10)
>80–89 46/349 (13.2%) 0.60 (0.43, 0.84) 0.82 (0.59, 1.14) 58/335 (17.3%) 0.50 (0.38, 0.67) 0.67 (0.51, 0.88)
>89–100 19/303 (6.3%) 0.29 (0.18, 0.46) 0.50 (0.31, 0.80) 22/296 (7.4%) 0.22 (0.14, 0.33) 0.36 (0.24, 0.55)
Trend: p < 0.001 p = 0.005 p < 0.001 p < 0.001
CONSUMES MEAT?
No 53/505 (10.5%) 1.00 [Reference] 1.00 [Reference] 70/490 (14.3%) 1.00 [Reference] 1.00 [Reference]
Yes 137/803 (17.1%) 1.63 (1.21, 2.19) 1.22 (0.92, 1.63) 204/773 (26.4%) 1.85 (1.44, 2.37) 1.41 (1.11, 1.78)
p = 0.001 p = 0.17 p < 0.001 p = 0.004
CONSUMES DAIRY?
No 58/551 (10.5%) 1.00 [Reference] 1.00 [Reference] 71/534 (13.3%) 1.00 [Reference] 1.00 [Reference]
Yes 131/753 (17.4%) 1.65 (1.24, 2.21) 1.27 (0.96, 1.69) 203/725 (28.0%) 2.11 (1.65, 2.69) 1.60 (1.26, 2.02)
p = 0.001 p = 0.10 p < 0.001 p < 0.001
TAKING A VITAMIN D SUPPLEMENT?
No 49/192 (25.5%) 1.00 [Reference] 1.00 [Reference] 63/186 (33.9%) 1.00 [Reference] 1.00 [Reference]
Yes 141/1,117 (12.6%) 0.50 (0.37, 0.66) 0.61 (0.46, 0.81) 211/1,078 (19.6%) 0.58 (0.46, 0.73) 0.70 (0.56, 0.87)
p < 0.001 p = 0.001 p < 0.001 p = 0.002
TALKING AN OMEGA-3 SUPPLEMENT?
No 87/464 (18.8%) 1.00 [Reference] 1.00 [Reference] 128/450 (28.4%) 1.00 [Reference] 1.00 [Reference]
Yes 103/845 (12.2%) 0.65 (0.50, 0.85) 0.87 (0.67, 1.12) 146/814 (17.9%) 0.63 (0.51, 0.78) 0.80 (0.66, 0.98)
p = 0.001 p = 0.28 p < 0.001 p = 0.031
PHYSICAL ACTIVITY, BY IPAQ
Low activity 86/391 (22.0%) 1.00 [Reference] 1.00 [Reference] 122/377 (32.4%) 1.00 [Reference] 1.00 [Reference]
Moderate activity 69/577 (12.0%) 0.54 (0.41, 0.73) 0.75 (0.55, 1.01) 97/556 (17.5%) 0.54 (0.43, 0.68) 0.74 (0.59, 0.93)
High activity 16/268 (6.0%) 0.27 (0.16, 0.45) 0.49 (0.30, 0.82) 30/261 (11.5%) 0.36 (0.25, 0.51) 0.60 (0.42, 0.87)
Trend: p < 0.001 p = 0.003 p < 0.001 p = 0.002
MEDITATES AT LEAST WEEKLY?
No 133/839 (15.9%) 1.00 [Reference] 1.00 [Reference] 198/817 (24.2%) 1.00 [Reference] 1.00 [Reference]
Yes 50/454 (11.0%) 0.70 (0.51, 0.94) 0.75 (0.56, 1.00) 70/432 (16.2%) 0.67 (0.52, 0.86) 0.73 (0.58, 0.92)
p = 0.019 p = 0.052 p = 0.001 p = 0.008
Analyses by log-binomial regression, estimating a prevalence ratio (PR) (95% CI). Adjusted models adjusted for age, P-MSSS, FSS, and use of antidepressant medication.
Figures in boldface denote statistical significance (p < 0.05). Figures in italics are p-values.
aAlcohol intake was categorized specific to sex, such that low alcohol intake was defined as <15 grams of alcohol per week, moderate was up to 30 grams alcohol per day for females
and up to 45 grams alcohol per day for males, and heavy was over 30 grams alcohol per day for females and over 45 grams alcohol per day for males.
BMI, body mass index; DHQ, Dietary Habits Questionnaire; FSS, Fatigue Severity Scale; IPAQ, International Physical Activity Questionnaire; PHQ, Patient Health Questionnaire; P-MSSS,
Patient Determined Multiple Sclerosis Severity Score.
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Being a smoker was significantly predictive of positive
depression screen and more severe depression at follow-up.
This finding parallels the association between smoking and
lower mental health-related quality of life, which we previously
demonstrated in people with MS (26). After adjusting for
potential confounders, we did not find an association between
smoking and subsequent change in depression risk, however,
while the clinical implications of smoking and depression require
further research, the evidence base is clear that smoking is
a major risk factor for the development and progression of
MS and other comorbidities (41, 42). Smokers commonly have
depression, and vice versa, people with depression are more
likely to smoke, and smoking cessation interventions are more
successful if management includes interventions for depression
(43). Being or becoming a non-smoker clearly has multiple direct
and indirect benefits for people with MS.
Intervention trials in the general population show that
improving diet quality, increasing exercise, sunlight exposure
(44), and supplementing with omega-3 and vitamin D are
effective adjunctive treatments to antidepressant medication
(45). Vitamin D and omega-3 supplementation was common
in this sample, with roughly three-quarters taking vitamin D
and two-thirds taking omega-3 supplements. This supplement
use is becoming quite common among MS patients, given
the abundance of research evidence suggesting a potential
protective association on MS onset and progression. While not
yet proven, and thus not recommended by medical practitioners
as a treatment against MS, such supplementation is a relatively
inexpensive and simple lifestyle modification for people to
undertake, and one withoutmaterial side effect, and consequently
it is frequently seen in MS cohorts.
Observational studies in the general population and MS
indicate that low vitamin D is a modifiable risk factor for
depression (46, 47). Our data at baseline and 2.5-years follow-
up found an association between supplementation with vitamin
D and risk of positive depression screen, and as well as severity of
depression.
A recent meta-analysis supports that omega-3 intake is
associated with a lower risk of depression (48). In line with the
literature in the general population, our data found an inverse
association between omega-3 supplementation and both the risk
of positive depression screen and severity of depression, though
not with change in depression state. The literature on health
benefits for people with MS is not consistent. While omega-3
supplementation has been associated with better health-related
quality of life and reduced disability among people with MS
(49), another study found no benefit for disability progression,
quality of life, relapses, MRI lesions or fatigue (50). A recent
pilot trial found no effect of omega-3 on depression in people
with MS (51). However, omega-3 supplementation is safe and
provides numerous health benefits across the life cycle and
in other diseases, such as cancer and autoimmune conditions
(52–54). Its effects are thought to be via immunomodulation,
anti-inflammation, neuroprotection and neurotransmission (55).
Reverse causality is possible, as people without depression are
more likely to engage in more healthy behaviors. Nonetheless,
our data and other studies support a possible link between
supplementation of omega-3, and mental and physical health
outcomes in people with MS (20, 49).
Healthy diet is critical for optimal neurological function (16),
evidenced in our growing knowledge of the connection between
the gut microbiome, neurotransmitters and mental health (56).
While we found no association between diet quality and
depression risk, there was a dose-response association between
diet quality and depression severity. Dose-response relationships
have been found between diet quality and depression in
the general population (57) and better diet quality has been
associated with improved mental health-related quality of life
in people with MS (58). Dairy, but not meat intake, was
associated with greater depression risk on PHQ-9 but not PHQ-
2. In our study, the relationship between diet and depression
risk may reflect reverse causality. The observed association
of dairy intake and depression risk is less clear and is likely
also to be affected by reverse causality. These results are
partly in line with previous work, including work showing
a vegan diet improved depression in the general population
(59). A whole food plant-based diet has been recommended
for people with MS and more widely for general health
(60). It is important for clinicians to consider dietary advice
as part of an effective management strategy for depression
(61).
Low physical activity was strongly associated with an
increased depression risk and depression severity. We did,
however, not find an association between physical activity and
change in depression risk. Our data reinforce findings that people
with MS who exercise regularly have better quality of life and
favorable depression scores (57, 62) consistent with findings in
the general population (63). The relationship between physical
activity and depression is likely bi-directional and we cannot
quantify the degree of reverse causality that may be present in
our data. However, the evidence base from clinical trials is strong
enough for clinicians to inform people with MS of the benefit
of regular physical activity (64). There is a synergistic benefit
to be gained through regular exercise on mood and to reduce
obesity and comorbid medical disorders for direct benefit in MS
(16, 65, 66).
Meta-analysis of meditation and mindfulness-based stress
reduction programs shows a benefit for depression across
the general population and for people with other chronic
illness (16, 67). For people with MS, mindfulness meditation
holds potential to improve immune function and reduce
inflammation (68). A recent randomized controlled trial
of mindfulness-based interventions improved depression and
quality of life, with gains maintained at long-term follow-up
(14). In line with these studies, we have shown meditation
is cross-sectionally associated with lower depression risk at
2.5-years follow-up, although our findings did not show
meditation to be associated with depression trajectory during
follow-up. This disparity may reflect the relative insensitivity
of our assessment of meditation, as well as the inherent
subjectivity of meditation. Thus, further longitudinal analyses,
ideally with rigorous assessment of meditation behavior, are
needed to assess the role of meditation in depression and
MS.
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A preventive medical approach to MS management, both
pharmacological and otherwise, is in line with the broad shift
toward early intervention in the disease course (69). At baseline
(20) and here at 2.5-years follow-up, the HOLISM study has
shown clinically and statistically significant associations between
key modifiable lifestyle risk factors and depression, as well as
better mental and physical health-related quality of life (20, 58).
Moreover, in another study of people with MS who attended
lifestyle modification workshops, we found showed improved
mental health-related quality of life at 1, 3 and 5 years follow-up
(70–72), also finding that those with greater adherence to lifestyle
modification had better outcomes. More complete data revealed
adherence to lifestyle changes and outcome improvements at 1
and 3 years follow-up, including stabilized disability, reduced
relapse rates, and better physical health-related quality of life
(72). These results are supported by work in other chronic
illnesses, finding depression was reduced in people with diabetes
and elevated coronary risk factors who underwent intensive
lifestyle modification (73). Thus, there is potential for lifestyle
factors like those assessed here to have positive effects on
depression. If validated in other samples and supported by
randomized controlled trials, such lifestyle modification could be
an additional point of intervention to improve depression among
people living with MS.
Strengths and Limitations
A major strength of our sample was the breadth of data and
exposure gradient for lifestyle factors and sociodemographics.
However, some subsets of data, such as severe depression
remained small. It may be that such severely depressed people
would not participate in this study and thus, our assessment
of the frequency and determinants of severe depression may be
affected. Our sample may be biased due to participants being
recruited via online platforms, potentially recruiting a healthier
and more actively engaged sample of people with MS at baseline
and follow-up. In addition, there was appreciable attrition
between baseline and follow-up reviews, with a retention rate of
56.8%. While there was some evidence that those retained in the
study engaged in more healthy behaviors like not smoking, other
behaviors like alcohol, physical activity and supplement use were
not materially different between the original sample and those
participating at follow-up, nor were clinical characteristics like
disability or fatigue materially different. However, significantly
more people with depression risk at baseline were lost to follow-
up, suggesting that our estimates of depression prevalence at
follow-up may underestimate the true prevalence, and that
associations with depression state may be affected by this
differential loss to follow-up.
Our data are self-reported so the potential for recall bias exists.
Reverse causality cannot be excluded from some associations
and may have contributed to some of our trajectory data.
However, the biological plausibility, dose-response effect and
results from existing literature supports a potential causal
relationship between several lifestyle factors and depression risk.
Our data have many strengths, we recruited and retained a
large sample size, including people with all types of MS from
geographically diverse backgrounds. Validated tools were used
wherever possible and potential confounders were adjusted for.
However, not all participants responded to every question and
thus, there was some missing data. Accordingly, all multivariate
models were complete-case analysis, restricted to those with data
on all model parameters.
A large proportion of this cohort (42–46%) was taking
immunomodulatory medications. This is fairly similar to
frequencies reported in other MS cohorts. The associations of
immunomodulatory medication use with depression state will
be described in another paper. However, our evidence indicates
that controlling for disability and fatigue is adequate to account
for clinical variability and its association with depression in this
sample.
Factors which might have impacted upon depression risk,
and which would have been useful to account for, but which
we did not have information, include addiction and drug use,
membership in community and other organizations, and local
environmental characteristics, particularly air/water and noise
pollution. Addiction and drug use are obviously quite relevant,
but we only queried tobacco and alcohol use. While it is possible
for some covariance of illicit drug use with tobacco/alcohol, our
failure to measure these exposures is a limitation. Membership
in community and other social organizations could also impact
upon depression, so data on this would have been a useful
analysis, but one which we unfortunately cannot examine.
Likewise, environmental and noise pollution would be of interest,
both for overall quality of life and potentially for its impacts
on physical activity and time outdoors. Future studies would be
strengthened by measuring these parameters.
Another element of interest is socioeconomic status,
since this can impact upon depression and modify the
relationship of other factors with depression. However,
we only measured this factor at follow-up, precluding a
more definitive assessment of its prospective relationship,
especially with change in depression state. Accordingly, we
do not control for it here, though it is examined in another
manuscript.
CONCLUSION
In a large prospective cohort study of people with MS
and depression, we have found evidence that a variety
of lifestyle factors are inversely associated with depression,
though of these, only alcohol, diet and supplement use were
independently associated with change in depression. These
results, if confirmed, suggest that some healthy lifestyle behaviors
may positively impact depression risk among people living
with MS.
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